Map claims to evidence strength, expert review status, uncertainty, and revision history. Confidence states: preliminary → evidence-backed → expert-reviewed → revised.
| Claim | Evidence | Expert status | Uncertainty | Confidence | Sources | Share |
|---|---|---|---|---|---|---|
| Potency assay ambiguity remains one of the central bottlenecks in therapeutic EV development. Without a mechanism-linked potency assay, batch release and comparability are weakened. | High | pending | Medium | evidence backed | ||
| Local and topical EV applications may be more practical than broad systemic regenerative EV therapy. Delivery route and exposure drive CMC burden and clinical feasibility. | Medium | pending | Low-medium | evidence backed | ||
| Engineered EV delivery platforms must demonstrate clear advantage over LNP, AAV, and other established delivery modalities. Capital and development timelines require differentiated delivery economics and biodistribution. | High | pending | Medium | preliminary | ||
| Unapproved exosome clinic products carry significant regulatory and patient-safety risk and are not a credible venture pathway. Therapeutic claims require IND-enabled GMP development, not cash-pay clinic economics. | High | documented | Low | evidence backed | ||
| EV manufacturing is improving but remains a CMC-heavy, non-commodity process—not plug-and-play biologics manufacturing. COGS, facility design, and comparability drive venture capital intensity and timeline risk. | High | pending | Medium | evidence backed | ||
| Isolation and purification method largely defines the therapeutic EV product identity. Process changes without comparability data are regulatory and investment red flags. | High | pending | Low | evidence backed |
Local and topical EV applications may be more practical than broad systemic regenerative EV therapy.
Delivery route and exposure drive CMC burden and clinical feasibility.
Aegle Therapeutics (2024). Aegle first patient dosed in AGLE-102 DEB trial
Topical allogeneic MSC-derived EV product for local wound treatment in dystrophic epidermolysis bullosa.
Open source →Supports claims: local_topical_more_practical
Aegle Therapeutics (2024). MSC EVs in Dystrophic Epidermolysis Bullosa (NCT04173650)
Phase 1/2A topical AGLE-102 for RDEB wounds with intra-subject controls.
Open source →Supports claims: local_topical_more_practical
Gimona M et al. (2017). Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use
Requirements for manufacturing, safety, and efficacy testing of EV therapeutics from laboratory to patient; MSC-EV translational strategies.
Open source →Supports claims: potency_assay_ambiguity, ev_manufacturing_not_plug_and_play, local_topical_more_practical
Example only: reviewers often flag potency assays that measure generic immunomodulation without linkage to intended MOA in the target indication.
No revisions yet. Revisions will appear after expert feedback updates claim text.